Swedish Orphan Biovitrum AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Swedish Orphan Biovitrum AB - overview
Established
2001
Location
Stockholm, -, Sweden
Primary Industry
Pharmaceuticals
About
Based in Stockholm, Sweden, Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company that was formed in 2010 through the merger of Swedish Orphan International and Biovitrum. In November 2006, Biovitrum raised SEK 770 million in an IPO, selling 7. 7 million shares at SEK 100 per share on Nasdaq Stockholm and eventually as Swedish Orphan Biovitrum AB, the firm listed its shares in the Large Cap segment at Nasdaq Stockholm under the ticker symbols BIOVF, and SOBI. The company has expanded by acquiring companies over the years including full rights for Kineret in 2013, Synagis, emapalumab and related assets, and Dova Pharmaceuticals in 2019.
Swedish Orphan Biovitrum AB is engaged in the research, development, manufacturing, and supply of drugs and products, intended for the therapeutic areas including Haematology and Immunology. The company also provides medications and pharmaceuticals for the treatment of genetic and metabolic diseases. Its key products include extended half-life factor replacement treatments, its prescribed treatment for haemophilia A and B.
Current Investors
AP-Fonden 4
Primary Industry
Pharmaceuticals
Sub Industries
Government, Biotechnology, Pharmaceuticals
Website
www.sobi.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Swedish Orphan Biovitrum AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Public to Private, Secondary Buyout | Lapsed/Withdrawn | Swedish Orphan Biovitrum AB | - | ||||||||
| LP Direct, PIPE | Completed | Swedish Orphan Biovitrum AB | - | ||||||||
| LP Direct, PIPE | Completed | Swedish Orphan Biovitrum AB | - | ||||||||
| Add-on, Trade Sale | Completed | Swedish Orphan International Holding AB | - | ||||||||
| PIPE, Secondary Buyout | Completed | Swedish Orphan Biovitrum AB | - |
Displaying 1 - 5 of 8
Swedish Orphan Biovitrum AB - employee data
Swedish Orphan Biovitrum AB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Director of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.